Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases

PHASE2CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Post Partum Hemorrhage
Interventions
DRUG

Misoprostol

patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)

DRUG

Tranexamic acid

patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)

DRUG

Oxytocin

patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)

Trial Locations (1)

Unknown

Faculty of Medicine, Cairo

All Listed Sponsors
lead

Cairo University

OTHER

NCT04117243 - Tranexamic Acid Versus Sublingual Misoprostol in Reducing Blood Loss During Elective CS in High Risk Cases | Biotech Hunter | Biotech Hunter